Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$47.81 USD

47.81
9,409,499

-0.04 (-0.08%)

Updated Aug 14, 2025 04:00 PM ET

After-Market: $47.86 +0.05 (0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (146 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Zacks Equity Research

Acceleron (XLRN) Q4 Loss Wider Than Expected, Revenues Beat

by Zacks Equity Research

Acceleron (XLRN) reports a wider loss in the fourth quarter of 2020 on higher costs and lower revenues.

Zacks Equity Research

Iovance (IOVA) Q4 Earnings Miss Estimates, Pipeline in Focus

by Zacks Equity Research

Iovance's (IOVA) fourth-quarter earnings miss estimates. The company is progressing well with development of its lead pipeline candidate.

Zacks Equity Research

Agios' (AGIO) Q4 Loss In Line, Revenues Surpass Estimates

by Zacks Equity Research

Agios' (AGIO) loss meets estimates in the fourth quarter of 2020 while revenues beat the same. Sale of leukemia drug, Tibsovo, rise both sequentially as well as year over year. Shares down.

Zacks Equity Research

Nektar (NKTR) Q4 Earnings and Revenues Top, Pipeline On Track

by Zacks Equity Research

Nektar (NKTR) reports encouraging fourth-quarter 2020 results. The company plans to initiate a new registrational study on its lead pipeline candidate, bempegaldesleukin, in 2021.

Zacks Equity Research

FATE Reports Wider-Than-Expected Q4 Loss on Higher Expenses

by Zacks Equity Research

FATE reports a wider Q4 loss on increased R&D expenses.

Zacks Equity Research

bluebird (BLUE) Q4 Loss Narrower than Expected, Sales Miss

by Zacks Equity Research

bluebird (BLUE) reports a narrower-than-expected loss but misses sales estimates in the fourth quarter of 2020.

Zacks Equity Research

Epizyme's (EPZM) Q4 Loss Wider than Expected, Sales Beat

by Zacks Equity Research

Epizyme (EPZM) incurs a wider-than-expected loss but beats sales estimates in the fourth quarter of 2020.

Zacks Equity Research

Corcept (CORT) Q4 Earnings In Line, Revenues Miss Estimates

by Zacks Equity Research

Corcept's (CORT) earnings meet estimates in the fourth quarter of 2020 while revenues miss the same.

Zacks Equity Research

Clovis (CLVS) Q4 Earnings Miss, Revenues Beat, Stock Down

by Zacks Equity Research

Clovis (CLVS) reports wider-than-expected loss for fourth-quarter 2020. Sales of the company's sole marketed drug, Rubraca, increase year over year.

Zacks Equity Research

Zacks Value Trader Highlights: Bristol Myers Squibb, Danaos Corp, DR Horton, PacWest Bancorp and Synchrony Financial

by Zacks Equity Research

Zacks Value Trader Highlights: Bristol Myers Squibb, Danaos Corp, DR Horton, PacWest Bancorp and Synchrony Financial

Tracey Ryniec headshot

The Most Basic Value Stock Screen Ever

by Tracey Ryniec

Looking for value stocks? Keep it simple with a basic value screen that still packs a lot of punch.

Zacks Equity Research

Nektar (NKTR) Teams Up With Merck for Head & Neck Cancer Study

by Zacks Equity Research

Nektar's (NKTR) shares up following a deal with Merck for a combination study of bempegaldesleukin with Keytruda for advanced head and neck cancer study.

Zacks Equity Research

Bristol Myers (BMY) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Bristol Myers (BMY) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

Prothena's (PRTA) Q4 Loss Narrower Than Expected, Revenues Beat

by Zacks Equity Research

Prothena (PRTA) beats on earnings in the fourth quarter of 2020 and surpasses sales estimates too.

Zacks Equity Research

Exelixis' (EXEL) Q4 Earnings Surpass Estimates, Sales Miss

by Zacks Equity Research

Exelixis (EXEL) beats on earnings in the fourth quarter but misses on revenues.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Biogen, Gilead Sciences, Regeneron Pharma, Bristol-Myers Squibb and Incyte

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Biogen, Gilead Sciences, Regeneron Pharma, Bristol-Myers Squibb and Incyte

Zacks Equity Research

Biotech Stock Roundup: Q4 Results of BMY, REGN, BIIB & Other Regulatory Updates

by Zacks Equity Research

Earnings of leading biotechs like Biogen (BIIB), Gilead (GILD) and Regeneron (REGN) dominate last week's headlines in the biotech sector.

Zacks Equity Research

Bristol Myers (BMY) Gets European Commission Nod for Inrebic

by Zacks Equity Research

The European Commission approves Bristol Myers' (BMY) Inrebic for the treatment of adult patients with newly diagnosed and previously treated myelofibrosis.

Zacks Equity Research

Corcept (CORT) Posts Preliminary '20 Results, Gives 2021 View

by Zacks Equity Research

Corcept (CORT) provides preliminary revenue figures for fourth-quarter and full-year 2020. The company also issues revenue guidance for 2021. Shares down in after-hours trading.

Zacks Equity Research

Bristol Myers (BMY) Gets FDA Approval for CAR T-Cell Therapy

by Zacks Equity Research

Bristol Myers (BMY) obtains FDA approval of CAR T cell therapy, Breyanzi, for the treatment of lymphoma.

Zacks Equity Research

Exelixis (EXEL) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on pipeline and guidance updates when Exelixis (EXEL) reports fourth-quarter 2020 results.

Sweta Killa headshot

Pharma ETFs in Focus Post Q4 Earnings

by Sweta Killa

Healthcare Q4 results seem robust given that it is the fourth-best sector from a revenue growth look and the sixth-strongest in terms of earnings growth.

Zacks Equity Research

Bristol-Myers (BMY) Q4 Earnings Beat, 2021 EPS View Raised

by Zacks Equity Research

Bristol-Myers (BMY) beats on earnings and sales in the fourth quarter on strength of Revlimid and Eliquis.

Zacks Equity Research

Bristol Myers Squibb (BMY) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Bristol Myers (BMY) delivered earnings and revenue surprises of 6.57% and 4.43%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Amgen (AMGN) Q4 Earnings & Sales Top, 2021 Outlook Dull

by Zacks Equity Research

Amgen (AMGN) beats Q4 estimates for both earnings and sales. Shares decline in after-hours trading.